Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus.
about
Hepatitis C Viral Infection in Children: Updated ReviewTreatment of chronic hepatitis C with direct-acting antivirals: The role of resistanceElbasvir/Grazoprevir: A Review of the Latest Agent in the Fight against Hepatitis CSystemic manifestations of hepatitis C infectionInterferon-Free Treatments for Chronic Hepatitis C Genotype 1 InfectionUtilization of animal models to investigate non-alcoholic steatohepatitis-associated hepatocellular carcinomaPrice and affordability of direct-acting antiviral regimens for hepatitis C virus in the United StatesKASL clinical practice guidelines: management of hepatitis CChallenging hepatitis C-infected liver transplant patientsClinical applications, limitations and future role of transient elastography in the management of liver disease.Sofosbuvir treatment and hepatitis C virus infectionAdvances in hepatitis C therapy: What is the current state - what come's next?Alcohol and Viral Hepatitis: Role of Lipid RaftsChronic Hepatitis C: An Overview of Evidence on Epidemiology and Management from a Brazilian Perspective.Virologic Tools for HCV Drug Resistance TestingUpdate on hepatitis C: Direct-acting antiviralsProfile of paritaprevir/ritonavir/ombitasvir plus dasabuvir in the treatment of chronic hepatitis C virus genotype 1 infectionInterferon-Free Hepatitis C Treatment before and after Liver Transplantation: The Role of HCV Drug ResistanceHCV Drug Resistance Challenges in Japan: The Role of Pre-Existing Variants and Emerging Resistant Strains in Direct Acting Antiviral TherapyThe hepatitis C virus epidemics in key populations (including people who inject drugs, prisoners and MSM): the use of direct-acting antivirals as treatment for preventionApproved Antiviral Drugs over the Past 50 YearsAnti-hepatitis C virus drugs and kidneyValue of Treating All Stages of Chronic Hepatitis C: A Comprehensive Review of Clinical and Economic EvidenceHIV/HCV Antiviral Drug Interactions in the Era of Direct-acting AntiviralsSuccinct guide to liver transplantation for medical studentsRecommendations for the Clinical Management of Hepatitis C in Iran: A Consensus-Based National GuidelineState of the Art, Unresolved Issues, and Future Research Directions in the Fight against Hepatitis C Virus: Perspectives for Screening, Diagnostics of Resistances, and ImmunizationClinical Laboratory Testing in the Era of Directly Acting Antiviral Therapies for Hepatitis CThe Daniel K. Inouye College of Pharmacy Scripts: Hepatitis C in 2015: Recent Advancements and Current ChallengesMultiple Introduction and Naturally Occuring Drug Resistance of HCV among HIV-Infected Intravenous Drug Users in Yunnan: An Origin of China's HIV/HCV EpidemicsGeno2pheno[HCV] - A Web-based Interpretation System to Support Hepatitis C Treatment Decisions in the Era of Direct-Acting Antiviral AgentsThe Brazilian comprehensive response to hepatitis C: from strategic thinking to access to interferon-free therapyRisk of end stage liver disease, hepatocellular carcinoma, and liver-related death by fibrosis stage in the hepatitis C Alaska Cohort.Hepatitis C virus infection.Hepatitis C and kidney disease: A narrative review.Ultrasound Elastography: Review of Techniques and Clinical Applications.Four weeks of paritaprevir/ritonavir/ombitasvir plus dasabuvir encountering dengue fever resulted in sustained virological response in an HCV patient: A case report.A quantitative metabolomics profiling approach for the noninvasive assessment of liver histology in patients with chronic hepatitis CIndian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection in 2015Outcomes and Costs of Treating Hepatitis C Patients in the Era of First Generation Protease Inhibitors - Results from the PAN Study.
P2860
Q26738856-441FF782-B774-4A83-A03A-3F81D73F2907Q26740219-96B1A119-0B1C-42B5-A0B7-98AE6A4974EFQ26741123-BEE47E7F-79C7-46E9-82C9-C67185B6C1DFQ26746040-E833E811-8DEA-4376-B7F7-7E25FF28A5B2Q26746563-9A331D23-C0F2-4DC6-BAD7-177FAEDAE104Q26748807-880188B1-844A-468D-B3C5-8A0BDDA56A03Q26749246-DE123B84-9BEA-4C67-B8F9-3B5ACB8271E4Q26752471-A84A8339-0B35-491A-ADE8-7D430EC3838BQ26765020-A5F28345-5A4E-4951-951A-C2EEB178684BQ26768262-04082F22-7ED0-4A4D-AC03-A8030D6A119FQ26770024-78AEECE2-4B6D-4A5D-B16C-425C7F0CEE19Q26770036-9DCFB306-4D12-4CF2-A00A-5E74395B287FQ26773213-96B6A4D5-7E83-46A0-84E7-CC221C4B079CQ26773585-E4FB4887-0D5C-48ED-AE65-DB80BA4D11E6Q26774374-3894FDCA-CF9E-416D-932A-6B8EB8D48F8CQ26775809-415E0BFF-96FB-4A5A-B064-5DF54C303663Q26775825-A1BE7FAB-6B47-4C24-8323-D2C1D22AE691Q26781331-BAC18D6B-3D02-46E2-B243-FE01D314B936Q26782405-013DF42A-67F6-4B4C-83E1-5B47DD375981Q26801456-991512B3-58F7-4A85-A50E-9753B12A0E0FQ27755387-A05A2B79-98C2-47EC-957C-16CC23C75E11Q28070279-622C30A9-A9CB-481E-91C6-42285411C0A1Q28072257-E361D72D-DBEF-4E26-9A3A-23E71717DD31Q28073489-01E7B402-8B7F-4A21-A65D-CB3B9B236A18Q28075352-9A67F266-D7CB-41EF-A236-85592178FC47Q28076883-0CDD921B-19F5-4509-A030-EA51663C1CEEQ28079102-9C5222D5-CA1E-4D65-BC44-E0D64EF681F1Q28080225-2197A635-6CB2-4434-BD57-9A2D6CC2F6A4Q28081108-64CEBFCB-C10A-4FD0-B510-7D79BF2607BDQ28550924-1AE44F3B-3A8D-4572-84F3-73BA0D8E8DBAQ28552269-FB79AFB0-A08B-421A-9521-C0975A0EACB1Q30061914-09F7BEFC-35C9-4C83-BF80-ECC43DF425D2Q30151351-54DED1D2-48A9-40FF-BF6B-418B61DDB265Q30235491-5082AAC3-1146-47EB-A0FC-37BADFB127CDQ30238652-503EB171-0EDE-4D57-9EB6-594C7A962489Q30358290-F298EB3D-3881-4C75-9C95-52669C4F5E9BQ30368260-C100DD63-737F-4F5F-93A2-28D25F22FE6CQ30375134-E1CA1EE0-EAAE-4516-8E8B-A91ACE6ECFACQ30375305-C586D45C-2A5D-477D-9DBB-B7FF13700E18Q30376341-99667DC5-EFA4-4A48-BF4E-0BB0B3CD5283
P2860
Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus.
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Hepatitis C guidance: AASLD-ID ...... fected with hepatitis C virus.
@ast
Hepatitis C guidance: AASLD-ID ...... fected with hepatitis C virus.
@en
Hepatitis C guidance: AASLD-ID ...... fected with hepatitis C virus.
@nl
type
label
Hepatitis C guidance: AASLD-ID ...... fected with hepatitis C virus.
@ast
Hepatitis C guidance: AASLD-ID ...... fected with hepatitis C virus.
@en
Hepatitis C guidance: AASLD-ID ...... fected with hepatitis C virus.
@nl
prefLabel
Hepatitis C guidance: AASLD-ID ...... fected with hepatitis C virus.
@ast
Hepatitis C guidance: AASLD-ID ...... fected with hepatitis C virus.
@en
Hepatitis C guidance: AASLD-ID ...... fected with hepatitis C virus.
@nl
P356
P1433
P1476
Hepatitis C guidance: AASLD-ID ...... fected with hepatitis C virus.
@en
P2093
AASLD/IDSA HCV Guidance Panel
P304
P356
10.1002/HEP.27950
P407
P577
2015-06-25T00:00:00Z